SEC Form 4 · accession 0001562180-15-000634
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven M Paul
Director
Period of report
Aug 3, 2015
Accepted (ET)
Aug 4, 2015 · 11:32 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 3, 2015 | S | 4,822 | $67.98 | D | 718,828 | D | |
| Common StockF3 | Aug 3, 2015 | S | 9,158 | $67.05 | D | 709,670 | D | |
| Common StockF4 | Aug 3, 2015 | S | 6,020 | $66.42 | D | 703,650 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $67.60 USD to $68.595 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $66.62 USD to $67.59 USD. The price reported above reflects the weighted average sale price.
- F4This transaction was executed in multiple trades at prices ranging from $66.00 USD to $66.58 USD. The price reported above reflects the weighted average sale price.